|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS11351 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-SPFH2 |
| 克隆性 | |
| 靶點(diǎn) | 詳見說(shuō)明書 |
| 適應(yīng)物種 | 詳見說(shuō)明書 |
| 形態(tài) | 詳見說(shuō)明書 |
| 宿主 | 詳見說(shuō)明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說(shuō)明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SPFH2 (201-280aa) |
產(chǎn)品訂購(gòu)信息：
英文名稱 Anti-SPFH2
中文名稱 內(nèi)質(zhì)網(wǎng)脂質(zhì)轉(zhuǎn)運(yùn)相關(guān)蛋白2抗體品牌
別 名 C8orf2; Chromosome 8 open reading frame 2; Endoplasmic reticulum lipid raft associated protein 2; Endoplasmic reticulum lipid raft-associated protein 2; ER lipid raft associated 2; ERLIN 2; Erlin-2; ERLIN2; ERLN2_HUMAN; HGNC:1356; MGC87072; NET32; SPFH 2; SPFH domain containing protein 2; SPFH domain family member 2; SPFH domain-containing protein 2; SPFH2; SPG18; Stomatin prohibitin flotillin HflC/K domain containing protein 2; Stomatin-prohibitin-flotillin-HflC/K domain-containing protein 2.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 通道蛋白 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 38kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SPFH2 (201-280aa)
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
內(nèi)質(zhì)網(wǎng)脂質(zhì)轉(zhuǎn)運(yùn)相關(guān)蛋白2抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 SPFH2 is a ubiquitously expressed 339 amino acid protein that belongs to the band 7/mec-2 family. Localized to lipid raft-like domains in the membrane of the endoplasmic reticulum (ER), SPFH2 plays a crucial role in the ER-associated degradation (ERAD) pathway that removes metabolically regulated and aberrant proteins from the ER. Specifically, SPFH2 associates with IP3R-I (Inositol 1,4,5-triphosphate receptor I), a substrate of the ERAD pathway, and facilitates its polyubiquitination and subsequent degradation. Three isoforms of SPFH2 are expressed due to alternative splicing events.
Function : Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs). Also involved in ITPR1 degradation by the ERAD pathway.
Subunit : Interacts with activated ITPR1, independently of the degree of ITPR1 polyubiquitination (By similarity). Forms a heteromeric complex with ERLIN1. In complex with ERLIN1, interacts with RNF170.
Subcellular Location : Endoplasmic reticulum membrane. Associated with lipid raft-like domains of the endoplasmic reticulum membrane.
Tissue Specificity : Ubiquitous.
DISEASE : Defects in ERLIN2 are the cause of spastic paraplegia autosomal recessive type 18 (SPG18) [MIM:611225]. A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG18 is a severe form with onset in early childhood. Most affected individuals have severe psychomotor retardation. Some may develop significant joint contractures.
Similarity : Belongs to the band 7/mec-2 family.
Database links : UniProtKB/Swiss-Prot: O94905.1
Anti-SP-A/FITC 熒光素標(biāo)記肺表面活性蛋白A抗體IgGMulti-class antibodies規(guī)格： 0.2ml
DDC (DOPA decarboxylase) 多巴胺脫羧酶(抗原)Multi-class antibodies規(guī)格： 0.5mg
原活化蛋白激酶p38抗體 Anti-P38 MAPK 0.1ml
surface layer protein 英文名稱： 乳酸細(xì)菌表面蛋白抗體 0.2ml
ECT2 英文名稱： 上皮細(xì)胞癌轉(zhuǎn)化蛋白2抗體 0.1ml
Rhesus antibody Rh phospho-NFKBIA(Se*/36) 磷酸化IKB alpha(Se*/36)抗體 規(guī)格 0.1ml
DDC (DOPA decarboxylase) 多巴胺脫羧酶(抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-Phospho-Progesterone Receptor (Ser190)/FITC 熒光素標(biāo)記磷酸化孕激素受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rabbit Anti-dog IgM/Gold 金標(biāo)記兔抗狗IgM (10nm/15nm)Multi-class antibodies規(guī)格： 2ml
角質(zhì)形成細(xì)胞生長(zhǎng)因子受體抗體 Anti-KGFR 0.2ml
Mouse Anti-Guinea pig IgG/PE-Cy7 PE-Cy7標(biāo)記的小鼠抗豚鼠IgG 0.1ml
FOXH1 英文名稱： 叉頭蛋白H1抗體 0.2ml
Rhesus antibody Rh Phospho-Stathmin(Ser25) 磷酸化原癌基因蛋白18 規(guī)格 0.1ml
Rabbit Anti-dog IgM/Gold 金標(biāo)記兔抗狗IgM (10nm/15nm)Multi-class antibodies規(guī)格： 2ml
JAK1(Tyrosine-protein kinase JAK1; Janus kinase 1) 蛋白質(zhì)酪氨酸激酶JAK-1抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-phospho-ADRB2(Ser346) 磷酸化能受體β2抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh phospho-CBL2(Tyr774) 磷酸化原癌蛋白CBL2抗體 規(guī)格 0.1ml
單組分AEC染色試劑盒 200片/20ml 需用甘油封固,紅色
VAPB 英文名稱： 囊泡相關(guān)膜蛋白相關(guān)的蛋白B 0.2ml
DNA polymerase mu 英文名稱： DNA聚合酶μ/DNA pol μ抗體 0.2ml
Anti-phospho-ADRB2(Ser346) 磷酸化能受體β2抗體Multi-class antibodies規(guī)格： 0.1ml
IL1RN Protein Rat 重組大鼠 IL-1RA / IL1RN 蛋白 (Fc 標(biāo)簽)
大鼠視網(wǎng)膜神經(jīng)節(jié)細(xì)胞完全培養(yǎng)基 100mL
HA Others H12N1 甲型 H12N1 (A/mallard duck/Alberta/342/1983) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
HL-7702人正常肝細(xì)胞 HL-7702 human normal liver cell 1640+10% FBS
CL-0435SF126(人細(xì)胞)5×106cells/瓶×2
NCI-H596(人肺腺鱗癌細(xì)胞) 5×106cells/瓶×2 cv-1(非洲綠猴腎細(xì)胞)
CM-R063大鼠腎小球內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
EPHA3 Others Mouse 小鼠 EphA3 (aa 569-984) 桿狀病毒-昆蟲細(xì)胞裂解液 (陽(yáng)性對(duì)照)
大鼠小腦星形膠質(zhì)細(xì)胞RA-c
非洲綠猴腎細(xì)胞;GL-37 細(xì)胞，CNE細(xì)胞 AsPC-1(轉(zhuǎn)移*腺癌細(xì)胞)
EB病毒轉(zhuǎn)化的人B淋巴細(xì)胞;HH-01
TNFRSF10B Others Mouse 小鼠 AILR2 / TNFRSF10B 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
內(nèi)質(zhì)網(wǎng)脂質(zhì)轉(zhuǎn)運(yùn)相關(guān)蛋白2抗體品牌 IL1RN Protein Rat 重組大鼠 IL-1RA / IL1RN 蛋白 (Fc 標(biāo)簽)
大鼠視網(wǎng)膜神經(jīng)節(jié)細(xì)胞完全培養(yǎng)基 100mL
HA Others H12N1 甲型 H12N1 (A/mallard duck/Alberta/342/1983) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
HL-7702人正常肝細(xì)胞 HL-7702 human normal liver cell 1640+10% FBS
CL-0435SF126(人細(xì)胞)5×106cells/瓶×2
NCI-H596(人肺腺鱗癌細(xì)胞) 5×106cells/瓶×2 cv-1(非洲綠猴腎細(xì)胞)
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 內(nèi)質(zhì)網(wǎng)脂質(zhì)轉(zhuǎn)運(yùn)相關(guān)蛋白2抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）內(nèi)質(zhì)網(wǎng)脂質(zhì)轉(zhuǎn)運(yùn)相關(guān)蛋白2抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
